Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

Por Lo Re, Giovanni, Santeufemia, Davide A., Foltran, Luisa, Bidoli, Ettore, Basso, Stefano M.M., Lumachi, Franco
Publicado no Oncotarget (2015)

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients

Por Ruzzo, Annamaria, Graziano, Francesco, Galli, Fabio, Giacomini, Elisa, Floriani, Irene, Galli, Francesca, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Publicado no Sci Rep (2014)